C H R O N I C M Y E L O P R O L I F E R A T I V E D I S O R D E R

16
CHRONIC MYELOPROLIFERATIVE DISORDER

description

 

Transcript of C H R O N I C M Y E L O P R O L I F E R A T I V E D I S O R D E R

Page 1: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

CHRONIC MYELOPROLIFERATIVE

DISORDER

Page 2: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

TYPES1. Chronic Myelogenous Leukemia

2. Polycythemia vera3. Essential Thrombocytosis

4. Primary Myelofibrosis

Page 3: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

CHRONIC MYELOGENOUS LEUKEMIA

Page 4: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

DESCRIPTIONPrimarily Adults ( 25-60 y/o )

Peak age 4th – 5th

> 90% Philadelphia Chromosome

t(9,22)(q34;q11)ABL-BCR gene translocationAffect Pluripotent stem cell

Net effect is Unregulated cell division & inhibition of apoptosis

Page 5: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

PHILADELPHIA CHROMOSOME

Page 6: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

Clinical Course Insidious Mild-Moderate Anemia

Microcytic to Macrocytic anemiaHypermetabolic state

Organomegaly Extramedullary Hematopoiesis Hepatosplenomegaly Mild Lymphadenopathy

Page 7: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

CLINICAL COURSE Median survival is 3 years 50% enter an Accelerated PhaseIncreasing anemia, thrombocytopenia, striking basophilia

6-12 months later AML - Blastic crisis

50% Blast crisis

Page 8: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

PBSMarked LeukocytosisPredominantly pmns, metamyelocytes, myelocytes

Less 10% are MyeloblastEosinophilia & BasophiliaThrombocytosis

DESCRIPTION

Page 9: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

DESCRIPTION BM Hypercellular 100%

Composed mostly Maturing Granulocytic precursors

Page 10: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

PBS- CML

Page 11: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

Extramedullary Hematopoiesis Hepatosplenomegaly Mild Lymphadenopathy

DESCRIPTION

Page 12: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

FEATURE LEUKEMOIDREACTION

CHRONIC MYELOGENOUSLEUKEMIA

1. WBC < 50 x 109/L > 50 x 109/L

2. Toxic Granulation

Positive Negative

3. Basophilia Absent Greater basophia

4. Cell Bands-prominent

Immature all stages, particularly myelocyte

5. LAP High > 100 Low < 10

6. Splenomegaly Absent Present

Philadelphia Chromosome

Absent Present

Page 13: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

TREATMENT BCR-ABL kinase inhibitors

May not prevent progression to crisis

Allogenic bone marrow transplantMost effective Tx

Page 14: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

POLYCYTHEMIA VERA Clonal D/O of pluripotent stem cell

Undetectable levels of eryhtropoietin

Increase in Myeloid Stem cells With progression Lead to

1. myelofibrosis2. Leukemic transformation

Page 15: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

POLYCYTHEMIA VERA Late Middle age group blood Viscosity Vascular stasis Thrombotic tendency & Hemorrhagic diasthesis

Gout , Pain on affected organ Death :

30% thrombotic complications – brain, heart

5-10% Bleeding

Page 16: C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R

DIAGNOSIS : All 3 or 2 of Major + 2 Minor MAJOR

Increased Total Erythrocyte Volume- Males > 36ml/Kg- Females > 32ml/Kg

Normal Arterial O2 saturation > 92%Splenomegaly

MINORThrombocytosis > 400 x 10 9/LLeukocytosis > 12 x 10 9 /L Increased NAP Increased Serum Vit B12 > 900 ug/L